Silence Therapeutics PLC (SLNCF) — SEC Filings
Silence Therapeutics PLC (SLNCF) — 41 SEC filings. Latest: 8-K/A (Dec 22, 2025). Includes 15 6-K, 9 8-K, 8 SC 13G/A.
View Silence Therapeutics PLC on SEC EDGAR
Overview
Silence Therapeutics PLC (SLNCF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Dec 22, 2025: Silence Therapeutics plc filed an amendment (8-K/A) on December 22, 2025, to a report originally dated December 14, 2025. The amendment pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certai
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Silence Therapeutics PLC is neutral.
Filing Type Overview
Silence Therapeutics PLC (SLNCF) has filed 1 8-K/A, 9 8-K, 3 10-Q, 1 DEF 14A, 1 10-K/A, 1 10-K, 15 6-K, 8 SC 13G/A, 1 SC 13D/A, 1 20-F with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of SLNCF's 34 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0.5M |
| Net Income | -$76.8M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $82.0M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Anish Surpur
- Dr. Gareth Jenkins
- Mr. Tooman
- Mark Rothera
- Dr. Anish Bhatnagar
- Dr. Gareth Baylis
- Richard Ian Griffiths
- Richard Griffiths
- Mr. Amaury Wittouck
Industry Context
The RNA therapeutics sector is characterized by rapid innovation and significant R&D investment, with companies often relying on substantial external funding and strategic partnerships. Silence Therapeutics operates in a competitive landscape where clinical trial success and regulatory approvals are paramount for commercial viability.
Top Tags
sec-filing (9) · financials (5) · Biotechnology (3) · financial-reporting (3) · corporate-governance (3) · amendment (3) · quarterly-report (3) · leadership-change (2) · executive-change (2) · personnel (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $76.8M | for the nine months ended September 30, 2025, increased from $57.6M in 2024 |
| Revenue | $0.5M | for the nine months ended September 30, 2025, down from $17.9M in 2024 |
| Research and Development Costs | $59.0M | for the nine months ended September 30, 2025, up from $45.8M in 2024 |
| Cash and Cash Equivalents | $82.0M | as of September 30, 2025, decreased from $121.3M at December 31, 2024 |
| Accumulated Deficit | $550.8M | as of September 30, 2025 |
| Cash Outflows from Operating Activities | $45.0M | for the nine months ended September 30, 2025 |
| Restructuring Charges | $1.3M | for the nine months ended September 30, 2025 |
| Ordinary Shares Outstanding | 141,701,848 | as of September 30, 2025 |
| Hansoh Collaboration Income | $0.5M | Decreased from $1.2M in Q2 2024 to $0.5M in Q2 2025, a 58.3% decline. |
| AstraZeneca Collaboration Income | $0.8M | Decreased from $1.5M in Q2 2024 to $0.8M in Q2 2025, a 46.7% decline. |
| Additional Paid-in Capital | $300.5M | Increased from $300.0M on Dec 31, 2024, to $300.5M on June 30, 2025, indicating capital raised. |
| ADSs Exercised | 19,000 | Number of American Depositary Shares exercised in 2024, contributing to capital. |
| Fiscal Year End | 2024-12-31 | Reporting period for executive compensation details. |
| Period of Report | 2025-06-26 | The period this DEF 14A filing pertains to. |
| Reporting Period End Date | 2025-03-31 | Latest financial data available |
Forward-Looking Statements
- {"claim":"Goldman Sachs will continue to hold a significant stake in Silence Therapeutics plc.","entity":"Goldman Sachs Group Inc.","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"Silence Therapeutics plc's stock price may experience minor fluctuations following this disclosure.","entity":"Silence Therapeutics plc","targetDate":"February 2024","confidence":"low"}
- {"claim":"Artal International S.C.A. will maintain a significant stake in Silence Therapeutics plc for the foreseeable future.","entity":"Artal International S.C.A.","targetDate":"December 31, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Silence Therapeutics PLC (SLNCF)?
Silence Therapeutics PLC has 41 recent SEC filings from Feb 2024 to Dec 2025, including 15 6-K, 9 8-K, 8 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SLNCF filings?
Across 41 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 36 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Silence Therapeutics PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Silence Therapeutics PLC (SLNCF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Silence Therapeutics PLC?
Key financial highlights from Silence Therapeutics PLC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SLNCF?
The investment thesis for SLNCF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Silence Therapeutics PLC?
Key executives identified across Silence Therapeutics PLC's filings include Dr. Anish Surpur, Dr. Gareth Jenkins, Mr. Tooman, Mark Rothera, Dr. Anish Bhatnagar and 4 others.
What are the main risk factors for Silence Therapeutics PLC stock?
Of SLNCF's 34 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Silence Therapeutics PLC?
Recent forward-looking statements from Silence Therapeutics PLC include guidance on {"claim":"Goldman Sachs will continue to hold a significant stake in Silence Therapeutics plc.","entity":"Goldman Sachs and 2 other predictions.